They also implied that 17-AAG was less effective at inhibiting breast cancer cell stemness than HDN-1 because 17-AAG did not inhibit the AKT-GSK3β-β-catenin cascade (Figure 6). This evidence concerns the gene AKT1 and breast cancer.